Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

The Associated Press November 17, 2010, 12:40PM ET

FDA panel backs new use for Gardasil vaccine

A federal health panel says evidence supports expanding use of Merck's Gardasil vaccine to prevent anal cancer in young men and women.

The panel of Food and Drug Administration advisers said a 4,000-patient study conducted by Merck & Co. Inc. shows the vaccine lowers the risk of anal cancer in men. They said these results can also be applied to women.

Anal cancer is relatively rare, affecting about 5,000 people in the U.S. each year.

Gardasil, Merck's top-selling vaccine, already is approved for prevention of cervical cancer and genital warts in girls and women aged 9 to 26. It's also approved for preventing genital warts in boys and men aged 9 to 26.

The vaccine works by blocking four of the most common strains of human papilloma virus, or HPV.

BW Mall - Sponsored Links

Buy a link now!